These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8347192)

  • 1. Treatment of Parkinson's disease.
    McFarland HR
    Neurology; 1993 May; 43(5):1056-7. PubMed ID: 8347192
    [No Abstract]   [Full Text] [Related]  

  • 2. Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline.
    Degli Esposti L; Piccinni C; Sangiorgi D; Nobili F; Buda S
    Neurol Sci; 2016 Feb; 37(2):227-34. PubMed ID: 26474874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical inquiries. What is the best initial treatment of Parkinson's disease?
    Schreck J; Kelsberg G; Rich J; Ward R
    J Fam Pract; 2003 Nov; 52(11):897-9. PubMed ID: 14599387
    [No Abstract]   [Full Text] [Related]  

  • 4. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study.
    Van Gerpen JA; Ahlskog JE
    Neurology; 2001 Jul; 57(2):368-9; author reply 369-70. PubMed ID: 11468339
    [No Abstract]   [Full Text] [Related]  

  • 5. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study.
    Ben-Shlomo Y; Lees A;
    Neurology; 2001 Jul; 57(2):369; author reply 369-70. PubMed ID: 11480425
    [No Abstract]   [Full Text] [Related]  

  • 6. Deprenyl in Parkinson's disease.
    Korczyn AD; Nisipeanu P
    Ann Neurol; 1996 Aug; 40(2):268-9. PubMed ID: 8773617
    [No Abstract]   [Full Text] [Related]  

  • 7. Current status of selegiline as a neuroprotective agent in Parkinson's disease.
    Olanow CW; Mytilineou C; Tatton W
    Mov Disord; 1998; 13 Suppl 1():55-8. PubMed ID: 9613720
    [No Abstract]   [Full Text] [Related]  

  • 8. Selegiline in Parkinson's disease.
    Calne DB
    BMJ; 1995 Dec; 311(7020):1583-4. PubMed ID: 8555790
    [No Abstract]   [Full Text] [Related]  

  • 9. Deprenyl as symptomatic therapy in Parkinson's disease.
    Golbe LI
    Clin Neuropharmacol; 1988 Oct; 11(5):387-400. PubMed ID: 3146432
    [No Abstract]   [Full Text] [Related]  

  • 10. Deprenyl and levodopa and Parkinson's disease progression.
    Fowler JS; Fazzini E; Volkow ND
    Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616
    [No Abstract]   [Full Text] [Related]  

  • 11. [Implication of piribedil (pronoran) in the treatment of Parkinson's disease; a clinical and pharmacoeconomic analysis].
    Mil'chakova AE; Popov GR; Bykov AV; Gekht AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):49-55. PubMed ID: 18567194
    [No Abstract]   [Full Text] [Related]  

  • 12. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
    Coyle J; Hobson P; Meara J
    J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):280; author reply 281-2. PubMed ID: 9703194
    [No Abstract]   [Full Text] [Related]  

  • 13. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
    Heinonen E; Myllylä V
    J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):280-2. PubMed ID: 9703195
    [No Abstract]   [Full Text] [Related]  

  • 14. Selegiline monotherapy in the treatment of Parkinson's disease.
    Koller WC
    Neurology; 1996 Dec; 47(6 Suppl 3):S196-9. PubMed ID: 8959988
    [No Abstract]   [Full Text] [Related]  

  • 15. Costs of Parkinson's disease and antiparkinsonian pharmacotherapy: an Italian cohort study.
    Winter Y; von Campenhausen S; Reese JP; Balzer-Geldsetzer M; Longo K; Spiga G; Boetzel K; Eggert K; Oertel WH; Dodel R; Barone P
    Neurodegener Dis; 2010; 7(6):365-72. PubMed ID: 20523028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease].
    Dubois B; Montastruc JL
    Rev Neurol (Paris); 1996 Feb; 152(2):103-5. PubMed ID: 8761616
    [No Abstract]   [Full Text] [Related]  

  • 17. [Parkinson's disease: cost-of-illness in an outpatient cohort].
    Reese JP; Winter Y; Balzer-Geldsetzer M; Bötzel K; Eggert K; Oertel WH; Dodel R; Campenhausen Sv
    Gesundheitswesen; 2011 Jan; 73(1):22-9. PubMed ID: 20229454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost-effect pharmacological studies of Parkinson's disease].
    Chikina ES; Belousov IuB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(11):68-72. PubMed ID: 16329642
    [No Abstract]   [Full Text] [Related]  

  • 20. Retention rate of selegiline in early Parkinson's disease: a retrospective survey.
    Keränen T; Mattila T; Luukkaala T; Kuusisto H
    Int J Clin Pract; 2012 Oct; 66(10):1014. PubMed ID: 22994335
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.